Diabetes / Metabolic
Diabetes and metabolic medicine updates, trial evidence, drug mechanisms and CPD resources across glucose lowering, weight management and cardiometabolic risk.
Latest Guidelines
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
Teplizumab is recommended for people aged 8 years and over with stage 2 type 1 diabetes to delay progression to stage 3; discuss with patients/families the…
2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease
This EASD guideline addresses 2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease in Diabetes / Metabolic. Use it to review current recommendation wording, eligibility criteria, and…
2023 ADA/EASD Consensus Report: Management of Hyperglycaemia in Type 2 Diabetes
Joint consensus update prioritising SGLT2 inhibitors and GLP-1 receptor agonists based on cardiovascular and renal comorbidities. Introduces individualised glucose targets and deprescribing guidance.
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services or trained general practice…
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m²…
Gestational Diabetes: Diagnosis and Treatment (NICE NG3)
Perform a 2-hour 75 g OGTT between 24–28 weeks in women with GDM risk factors; diagnose GDM if fasting glucose ≥5.6 mmol/L or 2-hour glucose ≥7.8…
Trial Radar
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Semaglutide weekly injections help children and teenagers lose weight better than placebo, alongside lifestyle support.
PHASE3A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with…
PHASE1To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Phase I trial testing inavolisib alone and combined with standard breast cancer treatments in patients with PIK3CA-mutant tumours.
PHASE3A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
CagriSema, a new weight-loss injection, is being tested against dummy medicine and two alternatives in a 1.5-year trial,…
Clinical News
Weekly type 2 diabetes jab could replace daily injections
Weekly insulin injections (icodec) offer potential to improve adherence by reducing dosing frequency from daily to once-weekly for…
07 Aug 2026Obesity rates have doubled in England since 1993 – what’s going on?
Obesity prevalence in England has doubled since 1993, representing an additional 7 million adults—a substantial public health burden…
22 Jul 2026Rise in women in their 20s developing Type 2 diabetes
Young women in their 20s in England are developing type 2 diabetes at increasing rates, representing a shift…
22 Jul 2026More young women in their 20s are getting type 2 diabetes
Type 2 diabetes incidence is rising significantly in women aged in their 20s in England, requiring heightened clinical…
Relevant Mechanisms
GLP-1 Receptor Agonism
GLP-1 Receptor Agonism is a clinically relevant Drug Science explainer. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal…
MechanismHMG-CoA Reductase — Statins
HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step…
MechanismPCSK9 Inhibition
PCSK9 Inhibition is a clinically relevant Drug Science explainer. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted…
MechanismSGLT-2 Inhibition
SGLT-2 Inhibition is a clinically relevant Drug Science explainer. Sodium-glucose cotransporter-2 (SGLT-2) is a high-capacity, low-affinity transporter expressed almost exclusively…
CPD, Podcasts & Webinars
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
webinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
podcastGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide…
podcastSGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, causing glycosuria with effects that extend beyond HbA1c…
cpd moduleNICE NG28: Type 2 Diabetes in Adults — 2024 Update
Apply NICE NG28 updates to type 2 diabetes treatment sequencing, including when SGLT2 inhibitors or GLP-1 receptor agonists…
cpd moduleCardiovascular Risk Reduction — Latest Evidence 2024
Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification. Apply statin, ezetimibe, PCSK9 inhibitor…
Follow Diabetes / Metabolic safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Diabetes / Metabolic
Choose guideline, trial, Drug Science and education updates for this specialty.